MA64013B1 - Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number
MA64013B1
MA64013B1 MA64013A MA64013A MA64013B1 MA 64013 B1 MA64013 B1 MA 64013B1 MA 64013 A MA64013 A MA 64013A MA 64013 A MA64013 A MA 64013A MA 64013 B1 MA64013 B1 MA 64013B1
Authority
MA
Morocco
Prior art keywords
solid forms
ynoyl
pyrazin
imidazo
pyrrolidin
Prior art date
Application number
MA64013A
Other languages
English (en)
Inventor
Jerry Evarts
Tjeerd Barf
Fritz Blatter
Tim INGALLINERA
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA64013(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma B.V. filed Critical Acerta Pharma B.V.
Publication of MA64013B1 publication Critical patent/MA64013B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

Dans certains modes de réalisation, l'invention concerne des formes solides cristallines, y compris des polymorphes, des hydrates et des formes de sel, de (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. Dans certains modes de réalisation, l'invention concerne également des compositions pharmaceutiques contenant les formes solides cristallines, et des méthodes de traitement d'affections ou de troubles par l'administration à un sujet d'une composition pharmaceutique qui comprend les formes, y compris des compositions pharmaceutiques et des méthodes pour surmonter les effets des agents réducteurs d'acide.
MA64013A 2015-07-02 2016-07-01 Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide MA64013B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28
EP23157244.7A EP4209493B1 (fr) 2015-07-02 2016-07-01 Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (1)

Publication Number Publication Date
MA64013B1 true MA64013B1 (fr) 2026-01-30

Family

ID=56363881

Family Applications (2)

Application Number Title Priority Date Filing Date
MA64013A MA64013B1 (fr) 2015-07-02 2016-07-01 Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (28)

Country Link
US (7) US9796721B2 (fr)
EP (4) EP3954690B1 (fr)
JP (3) JP6829215B2 (fr)
KR (2) KR102688052B1 (fr)
CN (2) CN113480542B (fr)
AU (3) AU2016286548B2 (fr)
CL (1) CL2017003445A1 (fr)
CY (3) CY1124519T1 (fr)
DK (4) DK4209493T3 (fr)
ES (4) ES2895802T3 (fr)
FI (2) FI4209493T3 (fr)
HR (4) HRP20200934T1 (fr)
HU (3) HUE062258T2 (fr)
IL (3) IL293821A (fr)
LT (4) LT3613745T (fr)
MA (2) MA64013B1 (fr)
MD (1) MD3317281T2 (fr)
MX (2) MX378495B (fr)
MY (1) MY193514A (fr)
PL (3) PL3954690T3 (fr)
PT (4) PT3613745T (fr)
RS (4) RS67620B1 (fr)
RU (1) RU2018103913A (fr)
SG (1) SG10201913796UA (fr)
SI (3) SI3613745T1 (fr)
SM (4) SMT202600010T1 (fr)
WO (1) WO2017002095A1 (fr)
ZA (2) ZA201800329B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3179991T3 (pl) * 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
HUE062258T2 (hu) 2015-07-02 2023-10-28 Acerta Pharma Bv (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamid szilárd alakjai és készítményei
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
US10899767B2 (en) * 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
WO2018115965A1 (fr) * 2016-12-23 2018-06-28 Acerta Pharma Bv Formes solides de composés d'imidazopyrazine
WO2018148961A1 (fr) * 2017-02-20 2018-08-23 杭州领业医药科技有限公司 Forme cristalline du sel acp-196, procédé de préparation, composition pharmaceutique et utilisation associés
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
WO2018229613A1 (fr) * 2017-06-13 2018-12-20 Dr. Reddy's Laboratories Limited Formes solides d'acalabrutinib et procédé de préparation correspondant
CA3073293A1 (fr) * 2017-08-29 2019-03-07 Apotex Inc. Nouvelles formes cristallines d'acalabrutinib
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
WO2019105359A1 (fr) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Forme cristalline de l'acalabrutinib, son procédé de préparation et son application
WO2019134455A1 (fr) 2018-01-05 2019-07-11 苏州科睿思制药有限公司 Nouvelle forme cristalline d'acalabrutinib, son procédé de préparation et son utilisation
WO2019159097A1 (fr) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Nouvelles formes polymorphes cristallines d'acalabrutinib
US20210087195A1 (en) * 2018-04-26 2021-03-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. New crystal form of acalbrutinib, preparation method therefor and use thereof
EP3587421A1 (fr) 2018-06-29 2020-01-01 Sandoz AG Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
IL312413B2 (en) 2018-08-29 2026-01-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
WO2020053795A2 (fr) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Procédé de préparation d'acalabrutinib et de ses intermédiaires
US12384784B2 (en) * 2018-09-25 2025-08-12 Cipla Limited Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
WO2020198429A1 (fr) 2019-03-27 2020-10-01 Assia Chemical Industries Ltd Formes à l'état solide d'acalabrutinib
WO2020225831A1 (fr) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
US12534467B2 (en) 2019-12-02 2026-01-27 Natco Pharma Limited Process for the preparation of Acalabrutinib
WO2021135346A1 (fr) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
US12583860B2 (en) 2020-02-26 2026-03-24 Apotex Inc. Processes for the preparation of multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour
WO2021239893A1 (fr) 2020-05-29 2021-12-02 Bend Research, Inc. Dispersion solide amorphe d'acalabrutinib
MX2022016341A (es) 2020-06-19 2023-01-24 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib.
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
WO2022153330A1 (fr) * 2021-01-13 2022-07-21 Natco Pharma Limited Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2023014817A1 (fr) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
WO2023205279A1 (fr) * 2022-04-19 2023-10-26 The Johns Hopkins University Spectroscopie raman améliorée avec addition de composés aromatiques
WO2024164066A1 (fr) * 2023-02-09 2024-08-15 Apotex Inc Formes cristallines de maléate d'acalabrutinib
WO2025125383A1 (fr) 2023-12-11 2025-06-19 Synthon B.V. Formes cristallines d'hydrogénomaléate d'acalabrutinib

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
EP2168968B1 (fr) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC Inhibiteurs hétérobicycliques de la protéine kinase à anneau bicyclique substitué en 6,6
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
PT1931346E (pt) 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
ES2365869T3 (es) 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1996193A2 (fr) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Traitement combiné avec un inhibiteur de kinase egfr et un agent sensibilisant les cellules tumorales aux effets des inhibiteurs de kinase egfr
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
EP2231147A2 (fr) 2007-12-13 2010-09-29 Novartis AG Combinaisons d'agents thérapeutiques pour le traitement du cancer
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
JP5764145B2 (ja) 2010-02-08 2015-08-12 メルク・シャープ・エンド・ドーム・ベー・フェー ８−メチル−１−フェニル−イミダゾル［１，５−ａ］ピラジン化合物
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3007787C (fr) 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
MX2014000130A (es) 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
CA2841887A1 (fr) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
EP3689878B1 (fr) * 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs btk
MX391121B (es) 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2751944T3 (es) * 2012-05-23 2020-04-02 Nerviano Medical Sciences Srl Proceso para la preparación de N-[5-(3,5-difluoro-bencil)-1H-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
US20140206681A1 (en) 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
HK1224173A1 (zh) 2013-03-14 2017-08-18 Pharmacyclics Llc 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2014143807A2 (fr) 2013-03-15 2014-09-18 Stromatt Scott Anticorps anti-cd37 et polythérapie par antagoniste de la voie bcr pour le traitement de malignités b et de troubles des lymphocytes b
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
EP2983670A4 (fr) 2013-04-08 2017-03-08 Pharmacyclics LLC Combinaison thérapeutique à base d'ibrutinib
WO2015018522A1 (fr) 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
WO2015057992A1 (fr) * 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
WO2015086642A1 (fr) 2013-12-13 2015-06-18 F. Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
WO2015110923A2 (fr) 2014-01-21 2015-07-30 Acerta Pharma B.V. Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
HUE062258T2 (hu) * 2015-07-02 2023-10-28 Acerta Pharma Bv (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamid szilárd alakjai és készítményei

Also Published As

Publication number Publication date
ES2797987T3 (es) 2020-12-04
DK3954690T3 (da) 2023-06-06
SMT202600010T1 (it) 2026-03-09
DK3613745T3 (da) 2021-10-18
HRP20200934T1 (hr) 2020-09-18
KR102688052B1 (ko) 2024-07-25
FI4209493T3 (fi) 2026-01-19
AU2022291635B2 (en) 2024-06-27
SI3317281T1 (sl) 2020-08-31
US20220177476A1 (en) 2022-06-09
KR20180048593A (ko) 2018-05-10
HUE049989T2 (hu) 2020-11-30
RS62455B1 (sr) 2021-11-30
RU2018103913A (ru) 2019-08-02
WO2017002095A1 (fr) 2017-01-05
US10167291B2 (en) 2019-01-01
US11059829B2 (en) 2021-07-13
HUE062258T2 (hu) 2023-10-28
KR20240115937A (ko) 2024-07-26
PT4209493T (pt) 2026-01-08
US20170029428A1 (en) 2017-02-02
SMT202300165T1 (it) 2023-07-20
US20180208596A1 (en) 2018-07-26
US20240199622A1 (en) 2024-06-20
MX2020014163A (es) 2022-09-29
PL3613745T3 (pl) 2022-01-31
SI3954690T1 (sl) 2023-07-31
EP3317281B1 (fr) 2020-04-22
AU2020277123B2 (en) 2022-09-29
SG10201913796UA (en) 2020-03-30
ZA202000300B (en) 2022-03-30
MY193514A (en) 2022-10-17
ES2895802T3 (es) 2022-02-22
HRP20230417T1 (hr) 2023-07-07
ZA201800329B (en) 2022-04-28
JP2018522877A (ja) 2018-08-16
EP3317281A1 (fr) 2018-05-09
CA2991096A1 (fr) 2017-01-05
MA50817B1 (fr) 2021-10-29
US11820777B2 (en) 2023-11-21
IL256633B (en) 2020-05-31
AU2022291635A1 (en) 2023-02-02
RS60411B1 (sr) 2020-07-31
US20200255437A1 (en) 2020-08-13
CL2017003445A1 (es) 2018-05-11
MA50817A (fr) 2021-04-21
PT3613745T (pt) 2021-10-14
SI3613745T1 (sl) 2021-12-31
AU2016286548A1 (en) 2018-02-01
CN113480542B (zh) 2025-07-25
CN108349978A (zh) 2018-07-31
RS67620B1 (sr) 2026-02-27
RS64195B1 (sr) 2023-06-30
US9796721B2 (en) 2017-10-24
EP3954690B1 (fr) 2023-04-05
JP7834584B2 (ja) 2026-03-24
AU2020277123A1 (en) 2020-12-24
LT4209493T (lt) 2026-01-26
CY1126103T1 (el) 2023-11-15
IL274066A (en) 2020-06-30
DK3317281T3 (da) 2020-06-15
JP2022120156A (ja) 2022-08-17
IL293821A (en) 2022-08-01
EP3954690A1 (fr) 2022-02-16
CN108349978B (zh) 2021-07-23
HUE056008T2 (hu) 2022-01-28
US20190337949A1 (en) 2019-11-07
LT3613745T (lt) 2021-10-11
CY1124519T1 (el) 2022-03-24
RU2018103913A3 (fr) 2019-12-31
ES2946489T3 (es) 2023-07-19
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
SMT202100597T1 (it) 2021-11-12
FI3954690T3 (fi) 2023-05-31
EP4209493B1 (fr) 2025-11-12
HK1250511A1 (en) 2018-12-21
PL3317281T3 (pl) 2020-11-02
PT3954690T (pt) 2023-06-06
SMT202000304T1 (it) 2020-07-08
LT3317281T (lt) 2020-07-27
HRP20260050T1 (hr) 2026-02-27
IL274066B (en) 2022-07-01
HRP20211511T1 (hr) 2021-12-24
PL3954690T3 (pl) 2023-08-14
US10640509B2 (en) 2020-05-05
MX378495B (es) 2025-03-11
EP4209493A1 (fr) 2023-07-12
US20220348582A1 (en) 2022-11-03
EP3613745A1 (fr) 2020-02-26
MD3317281T2 (ro) 2020-07-31
AU2016286548B2 (en) 2020-12-10
EP3613745B1 (fr) 2021-09-01
JP2021073235A (ja) 2021-05-13
IL256633A (en) 2018-02-28
JP6829215B2 (ja) 2021-02-10
ES3059433T3 (en) 2026-03-20
PT3317281T (pt) 2020-06-18
DK4209493T3 (da) 2026-02-02
MX2018000179A (es) 2018-06-27
JP7091494B2 (ja) 2022-06-27
LT3954690T (lt) 2023-05-25

Similar Documents

Publication Publication Date Title
MA64013B1 (fr) Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
NZ708593A (en) Novel pyrazole derivative
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2012135697A3 (fr) Nouveaux inhibiteurs de la rho-kinase et leurs procédés d'utilisation
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
IN2014KN00849A (fr)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2017011652A (es) (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.
IN2013MU01222A (fr)
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
IN2013MU01224A (fr)